Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1995 Jan;63(1):297–300. doi: 10.1128/iai.63.1.297-300.1995

Tumor necrosis factor (TNF)-dependent shedding of the p55 TNF receptor in a baboon model of bacteremia.

H Redl 1, G Schlag 1, G R Adolf 1, B Natmessnig 1, J Davies 1
PMCID: PMC172991  PMID: 7806369

Abstract

We have tested the hypothesis that the tumor necrosis factor (TNF) plays a significant role in vivo in TNF receptor shedding and studied the release of TNF-binding protein 1 (TNF-BP1), the soluble fragment of the 55- to 60-kDa TNF alpha (TNF) receptor, in a baboon model of Escherichia coli bacteremia, using three different doses of bacteria in acute infection (8 h) experiments (n [animals] = 11) and a single dose in a subchronic infection (72 h) experiment. In the subchronic infection study, one group of animals (n = 6) was pretreated with a neutralizing murine monoclonal antibody to TNF (CB0006). Concentrations of TNF and TNF-BP1 in plasma were determined in specific, monoclonal antibody-based immunoassays. Untreated animals (n = 6) showed undetectable TNF concentrations (< 10 pg/ml at baseline), whereas TNF-BP1 levels in plasma were in the range of 2 ng/ml, similar to concentrations observed in humans. Infusion of bacteria resulted in a rapid, dose-dependent increase in plasma TNF concentrations that reached a maximal level after 2 h and returned to baseline within 6 h. TNF-BP1 concentrations also showed a dose-dependent increase to peak concentrations three- to fivefold above baseline within 2 h but, in contrast to TNF levels, remained significantly elevated for up to 48 h. In animals pretreated with antibody CB0006, circulating TNF was completely neutralized, and TNF-BP1 was significantly reduced. We conclude that TNF-BP1 is released in bacteremia and that release in vivo is partially dependent on the presence of TNF.

Full Text

The Full Text of this article is available as a PDF (198.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aderka D., Engelmann H., Maor Y., Brakebusch C., Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med. 1992 Feb 1;175(2):323–329. doi: 10.1084/jem.175.2.323. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aderka D., Engelmann H., Shemer-Avni Y., Hornik V., Galil A., Sarov B., Wallach D. Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res. 1992 Jun;11(3):157–159. [PubMed] [Google Scholar]
  3. Aderka D., Englemann H., Hornik V., Skornick Y., Levo Y., Wallach D., Kushtai G. Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res. 1991 Oct 15;51(20):5602–5607. [PubMed] [Google Scholar]
  4. Adolf G. R., Apfler I. A monoclonal antibody-based enzyme immunoassay for quantitation of human tumor necrosis factor binding protein I, a soluble fragment of the 60 kDa TNF receptor, in biological fluids. J Immunol Methods. 1991 Sep 20;143(1):127–136. doi: 10.1016/0022-1759(91)90281-j. [DOI] [PubMed] [Google Scholar]
  5. Adolf G. R., Frühbeis B. Monoclonal antibodies to soluble human TNF receptor (TNF binding protein) enhance its ability to block TNF toxicity. Cytokine. 1992 May;4(3):180–184. doi: 10.1016/1043-4666(92)90053-t. [DOI] [PubMed] [Google Scholar]
  6. Engelberts I., Stephens S., Francot G. J., van der Linden C. J., Buurman W. A. Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet. 1991 Aug 24;338(8765):515–516. doi: 10.1016/0140-6736(91)90591-c. [DOI] [PubMed] [Google Scholar]
  7. Engelmann H., Novick D., Wallach D. Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990 Jan 25;265(3):1531–1536. [PubMed] [Google Scholar]
  8. Fernandez-Botran R. Soluble cytokine receptors: their role in immunoregulation. FASEB J. 1991 Aug;5(11):2567–2574. doi: 10.1096/fasebj.5.11.1868981. [DOI] [PubMed] [Google Scholar]
  9. Fong Y., Lowry S. F. Tumor necrosis factor in the pathophysiology of infection and sepsis. Clin Immunol Immunopathol. 1990 May;55(2):157–170. doi: 10.1016/0090-1229(90)90094-7. [DOI] [PubMed] [Google Scholar]
  10. Gullberg U., Lantz M., Lindvall L., Olsson I., Himmler A. Involvement of an Asn/Val cleavage site in the production of a soluble form of a human tumor necrosis factor (TNF) receptor. Site-directed mutagenesis of a putative cleavage site in the p55 TNF receptor chain. Eur J Cell Biol. 1992 Aug;58(2):307–312. [PubMed] [Google Scholar]
  11. Kalinkovich A., Engelmann H., Harpaz N., Burstein R., Barak V., Kalickman I., Wallach D., Bentwich Z. Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin Exp Immunol. 1992 Sep;89(3):351–355. doi: 10.1111/j.1365-2249.1992.tb06961.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Lantz M., Malik S., Slevin M. L., Olsson I. Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine. 1990 Nov;2(6):402–406. doi: 10.1016/1043-4666(90)90048-x. [DOI] [PubMed] [Google Scholar]
  13. Lantz M., Thysell H., Nilsson E., Olsson I. On the binding of tumor necrosis factor (TNF) to heparin and the release in vivo of the TNF-binding protein I by heparin. J Clin Invest. 1991 Dec;88(6):2026–2031. doi: 10.1172/JCI115530. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
  14. Peetre C., Thysell H., Grubb A., Olsson I. A tumor necrosis factor binding protein is present in human biological fluids. Eur J Haematol. 1988 Nov;41(5):414–419. doi: 10.1111/j.1600-0609.1988.tb00220.x. [DOI] [PubMed] [Google Scholar]
  15. Porteu F., Nathan C. Shedding of tumor necrosis factor receptors by activated human neutrophils. J Exp Med. 1990 Aug 1;172(2):599–607. doi: 10.1084/jem.172.2.599. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Redl H., Bahrami S., Leichtfried G., Schlag G. Special collection and storage tubes for blood endotoxin and cytokine measurements. Clin Chem. 1992 May;38(5):764–765. [PubMed] [Google Scholar]
  17. Redl H., Schlag G., Ceska M., Davies J., Buurman W. A. Interleukin-8 release in baboon septicemia is partially dependent on tumor necrosis factor. J Infect Dis. 1993 Jun;167(6):1464–1466. doi: 10.1093/infdis/167.6.1464. [DOI] [PubMed] [Google Scholar]
  18. Schlag G., Redl H., Hallström S., Radmore K., Davies J. Hyperdynamic sepsis in baboons: I. Aspects of hemodynamics. Circ Shock. 1991 Jul;34(3):311–318. [PubMed] [Google Scholar]
  19. Schlag G., Redl H., van Vuuren C. J., Davies J. Hyperdynamic sepsis in baboons: II. Relation of organ damage to severity of sepsis evaluated by a newly developed morphological scoring system. Circ Shock. 1992 Dec;38(4):253–263. [PubMed] [Google Scholar]
  20. Seckinger P., Isaaz S., Dayer J. M. A human inhibitor of tumor necrosis factor alpha. J Exp Med. 1988 Apr 1;167(4):1511–1516. doi: 10.1084/jem.167.4.1511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Shapiro L., Clark B. D., Orencole S. F., Poutsiaka D. D., Granowitz E. V., Dinarello C. A. Detection of tumor necrosis factor soluble receptor p55 in blood samples from healthy and endotoxemic humans. J Infect Dis. 1993 Jun;167(6):1344–1350. doi: 10.1093/infdis/167.6.1344. [DOI] [PubMed] [Google Scholar]
  22. Tartaglia L. A., Goeddel D. V. Two TNF receptors. Immunol Today. 1992 May;13(5):151–153. doi: 10.1016/0167-5699(92)90116-O. [DOI] [PubMed] [Google Scholar]
  23. Tracey K. J. TNF and other cytokines in the metabolism of septic shock and cachexia. Clin Nutr. 1992 Feb;11(1):1–11. doi: 10.1016/0261-5614(92)90056-v. [DOI] [PubMed] [Google Scholar]
  24. Tracey K. J. Tumor necrosis factor (cachectin) in the biology of septic shock syndrome. Circ Shock. 1991 Oct;35(2):123–128. [PubMed] [Google Scholar]
  25. Van Zee K. J., Kohno T., Fischer E., Rock C. S., Moldawer L. L., Lowry S. F. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo. Proc Natl Acad Sci U S A. 1992 Jun 1;89(11):4845–4849. doi: 10.1073/pnas.89.11.4845. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES